



## Caribou Biosciences to Participate in Upcoming Investor Conferences

August 29, 2023

BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](#) (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's participation in the following investor conferences:

- Citi 18<sup>th</sup> Annual BioPharma Conference, Boston, MA  
September 6, 2023
- Wells Fargo Healthcare Conference, Boston, MA  
September 7, 2023, 8:00 am EDT
- Morgan Stanley 21<sup>st</sup> Annual Global Healthcare Conference, New York, NY  
September 11, 2023
- Jefferies Cell & Genetic Medicine Summit, New York, NY  
September 26-27, 2023

For more information and links to available webcasts, visit the [Events](#) page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the events.

### **About Caribou's novel next-generation CRISPR platform**

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNA; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

### **About Caribou Biosciences, Inc.**

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit [www.cariboubio.com](http://www.cariboubio.com).

### **Caribou Biosciences, Inc. contacts:**

#### **Investors:**

Amy Figueroa, CFA  
[investor.relations@cariboubio.com](mailto:investor.relations@cariboubio.com)

#### **Media:**

Peggy Vorwald, PhD  
[media@cariboubio.com](mailto:media@cariboubio.com)